Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

A major American medical device manufacturer is investing $110 million to expand production in Nebraska as part of an effort ...

Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.

Biopharmaceutical artificial intelligence startup Owkin Inc. said today it’s making a series of autonomous agents focused on ...

Metastasis-directed stereotactic radiotherapy alongside biological cancer therapy appears safe, new data show.

The Food and Drug Administration said it will be taking steps to speed up the approval process for developing generic biological drugs, an effort aimed at increasing cheaper competition among ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

Biologic medicines—drugs with complex molecules developed in living cells—have saved lives and improved the quality of life for millions of Americans. Yet despite their value, problems in the industry ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and ...

In Gattaca, the 1997 sci-fi classic, a pair of siblings—one genetically engineered for perfection, the other naturally born—illustrate a dystopian vision where DNA determines destiny. The "in-valid" ...